Briefing: India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top

On March 23, 2026, Indian generic drugmakers are set to launch a series of weight-loss medications that could significantly undercut the pricing of Novo Nordisk's GLP-1 products.

This move introduces a competitive dynamic in the weight-loss drug sector, where Novo Nordisk has maintained a strong market presence with its brands Ozempic and WeGovy.

The implications for market share and pricing strategies will be critical, as the introduction of lower-cost alternatives may affect the overall capacity and throughput of existing supply chains.